Med. praxi. 2014;11(3):97-98

Fixed combination: can cardiovascular risk be reduced by 50%?

doc.MUDr.Filip Málek, Ph.D., MBA
Kardiovaskulární centrum, Nemocnice Na Homolce, Praha

Individual pharmacotherapy involving antihypertensive drugs, statin, and acetylsalicylic acid demonstrably reduces the risk of cardiovascular

diseases in secondary prevention and in primary prevention in individuals with a high risk. It is assumed that the use of these

agents alone or in a fixed combination is capable of reducing the risk of cardiovascular events by up to 50–60 %. Furthermore, it is assumed

that the use of these drugs coupled with adherence to healthy lifestyle practices (dietary and lifestyle measures) is capable of

reducing the cardiovascular risk by up to 70–80 %. The largest experience thus far has been with a combination of two antihypertensive

drugs and an antihypertensive–statin combination.

Keywords: combination therapy, fixed combination, cardiovascular risk

Published: May 15, 2014  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Málek F. Fixed combination: can cardiovascular risk be reduced by 50%? Med. praxi. 2014;11(3):97-98.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Working Group on the Summit on Combination Therapy for CVD. Combination pharmacotherapy to prevent cardiovascular disease: present status and challenges. Eur Heart J doi: 10.1093/eurheartj/eht407.
    2. Yusuf S. Two decades of progress in preventiv vascular disease. Lancet 2002; 360: 2-3. Go to original source... Go to PubMed...
    3. Wald NJ, Law MR. A strategy to reduce cardiovascular disease by more than 80% BMJ 2003; 326: 1419.
    4. Gradman AH, Basile JN, Carter BL, Barkis GL. Combination therapy in hypertension J Am Soc Hypertens 2010; 4(2): 90-98. Go to original source... Go to PubMed...
    5. Filipovský J, Widimský J jr., Ceral J. Diagnostické a lečebné postupy u arterialní hypertenze - verze 2012. Doporučení České společnosti pro hypertenzi. Hypertenze a kardiovaskulární prevence 2012; 3: 1-16.
    6. Souček M. Léčba hypertenze fixní kombinací - nové důkazy Interní medicína pro praxi 2009; 11(9): 369-375.
    7. Patel A and ADVANCE Collaborative Group. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcome in patients with type 2 diabetes mellitus (the ADVANCE trial). The Lancet 2007; 370: 829-840. Go to original source... Go to PubMed...
    8. Poulter NR, Peters R, Fletcher AE, et al. Role of blood pressure and other variables in the differential cardiovascular ebeny rates noted in Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA). Lancet 2005; 366: 907-913. Go to original source... Go to PubMed...
    9. Jamerson KA, Weber MA, Bakris GL, et al. For the ACCOMPLISH Trial Investigators. Benazepril plus Amlodipin or Hydrochlorothiazide for Hypertension in High Risk Patients. N Engl J Med 2008; 359: 2417-2428. Go to original source... Go to PubMed...
    10. Sever PS, Dahlöf B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations in the Anglo-Scandinavian Cardiac Outcomes trial: Lipid Lowering Arm (ASCOT-LLA): a multicenter randomised controlled trial. Lancet 2003; 361: 1149-1158. Go to original source... Go to PubMed...
    11. Thom S, Poulter NR, Field J, et al. Effects of a fixed-dose combination strategy on adherence and risk factors in patients with or at high risk of CVD: the UMPIRE randomized clinical trial. JAMA 2013; 310(9): 918-29. Go to original source... Go to PubMed...
    12. Charan J, Goyal JP, Saxena D. Effect of polypill on cardiovascular parameters: Systematic review and meta-analysis. J Cardiovasc Dis Res 2013; 4(2): 92-97. Go to original source... Go to PubMed...

    Return to the content


    Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.